Dr. Reddy's Laboratories Limited (FRA:RDDA)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.57B -9.4% |
| Revenue (ttm) | 3.11B +3.2% |
| Net Income | 396.34M -24.2% |
| EPS | 0.48 -24.1% |
| Shares Out | n/a |
| PE Ratio | 24.13 |
| Forward PE | 24.05 |
| Dividend | 0.06 (0.53%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | n/a |
| Open | 11.10 |
| Previous Close | 11.20 |
| Day's Range | 11.10 - 11.10 |
| 52-Week Range | 10.50 - 13.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In fiscal year 2026, Dr. Reddy's Laboratories's revenue was 335.93 billion, an increase of 3.19% compared to the previous year's 325.54 billion. Earnings were 42.85 billion, a decrease of -24.22%.
Financial numbers in INR Financial StatementsNews
Dr. Reddy's files 20-F annual report with US SEC for fiscal year ended March 31, 2026
Dr. Reddy's Laboratories has filed its Form 20-F annual report with the United States Securities and Exchange Commission (SEC), the company announced on May 30, 2026. The filing contains consolidated…
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 29, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NY...
Dr Reddy’s to ring closing bell at NYSE to mark 25 years of its listing
Dr Reddy’s Laboratories will ring the NYSE closing bell on May 30 to mark 25 years since its 2001 listing, a first for an Asian pharma firm outside Japan.
Dr. Reddy's Laboratories to ring the Closing Bell at NYSE for 25th listing anniversary
Dr. Reddy’s Laboratories Ltd. is set to ring the Closing Bell® at the New York Stock Exchange (NYSE) on May 29, 2026, marking 25 years since its listing. The company…
Dr Reddy’s rolls out oral semaglutide in India
Dr Reddy’s launches oral semaglutide biosimilar Obeda in India for Type 2 diabetes, CDSCO-approved; once-daily tablets priced Rs 99–225 (3/7/14 mg).
Dr. Reddy's (RDY) Introduces Generic Semaglutide Injection in Canada
Dr. Reddy's (RDY) Introduces Generic Semaglutide Injection in Canada
Dr. Reddy’s launches generic Semaglutide injection in Canada
Dr. Reddy’s (RDY) Laboratories announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy’s is among the first companies to introduce a generic Semaglutide Injection in the Canadia...
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
HYDERABAD, India & MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $RDY #DrReddy--Dr. Reddy's Laboratories Ltd. a global pharmaceutical company, today announced the launch of its generic Semaglutide Injecti...
Dr. Reddy's Laboratories launches generic Semaglutide Injection in Canada
Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, has announced the launch of its generic Semaglutide Injection in Canada. This development follows the receipt of the Notice of Complianc...
Pharma Stocks Today, May 15: Dr. Reddy’s Lab rises 1.32%, Lupin gains 1.19%, Strides Pharma falls 2.35%
Pharmaceutical stocks traded mixed on May 15 2026 in the early morning session. The BSE Healthcare index declined 0.15% to 47,037.86, while the broader market showed mild positive movement. The…
Dr. Reddy's Laboratories Q4 Earnings Call Highlights
Dr. Reddy's Laboratories NYSE: RDY reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomi...
Dr Reddy's, Dixon Technology & more: Top stocks to watch today
Morgan Stanley maintained an equal-weight rating on Dr Reddy’s Labs, citing missed Q4FY26 estimates and a slight delay in Semaglutide ramp-up. Kotak Institutional Equities recommended buying Dixon Tec...
Dr Reddy's Laboratories Ltd (RDY) Stock Up 4.2% and Still Undervalued -- GF Score: 90/100
Dr Reddy's Laboratories Ltd (RDY) Stock Up 4.2% and Still Undervalued -- GF Score: 90/100
Dr. Reddy's Laboratories (RDY) Set to Launch Generic Ozempic in Canada
Dr. Reddy's Laboratories (RDY) Set to Launch Generic Ozempic in Canada
Dr Reddy’s Labs Q4 net profit plunges 86%
Dr Reddy’s Labs Q4FY26 net profit fell 86% to Rs 221 crore as revenue dropped 12% to Rs 7,516 crore, hit by lower Revlimid sales in North America.
Dr Reddy's makes earnings call audio recording available for Q4 FY26
Dr. Reddy's Laboratories disclosed the availability of an audio recording from its earnings call held on May 12, 2026, discussing financial results for the quarter ended March 31, 2026. The…
Dr. Reddy's (RDY) Reports Q4 Earnings with Revenue Miss
Dr. Reddy's (RDY) Reports Q4 Earnings with Revenue Miss
Dr. Reddy's Laboratories Transcript: Q4 25/26
FY 2026 saw record revenues and double-digit base business growth, offset by lenalidomide headwinds and one-time charges. Strategic launches, especially semaglutide in Canada and India, and robust emerging market growth support a positive FY 2027 outlook.
Dr. Reddy's Laboratories Quarterly report: Q4 2026
Dr. Reddy's Laboratories has published its Q4 2026 quarterly earnings report on May 12, 2026.
Dr. Reddy's Laboratories Slides: Q4 2026
Dr. Reddy's Laboratories has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 12, 2026.
Dr. Reddy's Laboratories Annual report: Q4 2026
Dr. Reddy's Laboratories has published its Q4 2026 annual report on May 12, 2026.
Dr. Reddy’s Laboratories Q4 Results: Net profit falls 86% YoY to Rs 220.5 crore, revenue down 11.6%
Dr. Reddy's Laboratories reported a weak performance for the fourth quarter ended March 2026, with profit and revenue declining on a year-on-year (YoY) basis. The company’s earnings were impacted by…
Indian drugmaker Dr Reddy's posts quarterly profit slump
Indian drugmaker Dr Reddy's reported an 86% slump in quarterly profit on Tuesday, hurt by pricing pressure and increasing competition in its key U.S. market.
Top Q4 results today, May 12: Tata Power, Dr Reddy's Laboratories, Dixon Technologies, Torrent Power among key companies to announce earnings
A fresh batch of companies is set to announce their January-March quarter (Q4 FY26) earnings on Tuesday, May 12, 2026. Key companies scheduled to report their quarterly numbers include Tata…
Dr. Reddy's Laboratories grants over 1.19 million stock options to employees
Dr. Reddy's Laboratories has announced the approval of stock options for eligible employees under its Employees Stock Option Schemes. The Nomination, Governance and Compensation Committee of the Board...